Exposure–Bleeding Count Modeling of Emicizumab for the Prophylaxis of Bleeding in Persons with Hemophilia A with/Without Inhibitors Against Factor VIII

BACKGROUND AND OBJECTIVE: Emicizumab is a monoclonal antibody that bridges activated coagulation factor IX and factor X to restore effective hemostasis in persons with hemophilia A. It is indicated for routine prophylaxis of bleeding episodes in persons with hemophilia A. The aim of the present stud...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Clin Pharmacokinet
Egile Nagusiak: Jonsson, Fredrik, Schmitt, Christophe, Petry, Claire, Mercier, Francois, Frey, Nicolas, Retout, Sylvie
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Springer International Publishing 2021
Gaiak:
Original Research Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC8249270/
https://ncbi.nlm.nih.gov/pubmed/33709296
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40262-021-01006-0
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak